Logo

American Heart Association

  37
  0


Final ID:

Terrific Treatments for Transthyretin Cardiac Amyloidosis

  • Sarswat, Nitasha  ( University of Chicago , Chicago , Illinois , United States )
  • Dasgupta, Noel  ( Indiana University , Indianapolis , Indiana , United States )
  • Author Disclosures:
    Nitasha Sarswat: DO have relevant financial relationships ; Research Funding (PI or named investigator):Pfizer:Active (exists now) ; Advisor:AstraZeneca:Active (exists now) ; Research Funding (PI or named investigator):AstraZeneca:Active (exists now) ; Advisor:Alnylam:Active (exists now) ; Advisor:BridgeBio:Active (exists now) ; Advisor:NovoNordisk:Active (exists now) ; Research Funding (PI or named investigator):Intellia:Active (exists now) ; Research Funding (PI or named investigator):NovoNordisk:Active (exists now) ; Research Funding (PI or named investigator):Alnylam:Active (exists now) ; Research Funding (PI or named investigator):BridgeBio:Active (exists now) | Noel Dasgupta: No Answer
Meeting Info:

Scientific Sessions 2025

2025

New Orleans, Louisiana

More abstracts from these authors:
Primary results from the phase 2 randomized, placebo controlled, blinded trial of the monoclonal antibody coramitug in transthyretin amyloid cardiomyopathy (ATTR-CM)

Fontana Marianna, Kar Soumitra, Revanna Manjunatha, Sarswat Nitasha, Tsujita Kenichi, Maurer Mathew, Garcia-pavia Pablo, Grogan Martha, Shah Sanjiv, Engelmann Mads, Hovingh G. Kees, Kristen Arnt, Lim-watson Michelle, Malling Brian

Contemporary Insights on Diagnosing and Treating Transthyretin Cardiac Amyloidosis: How I Think, How I Treat

Masri Ahmad, Sarswat Nitasha

You have to be authorized to contact abstract author. Please, Login
Not Available